Repeated imaging with positron emission tomography-computed tomography (PET-CT) is associated with cumulative exposure to substantial doses of radiation. Furthermore, PET-CT is an expensive and limited resource in many institutions. We conducted a retrospective analysis to evaluate whether limited PET-CT focused on the initially involved field of view (FOV) at diagnosis, corresponding to an above- or below-the-diaphragm scan, is sufficient for follow-up of patients with Hodgkin (HL) and aggressive non-Hodgkin lymphoma (NHL). One hundred thirty-one examinations of 44 patients with early-stage (I-II) HL (n = 27) and aggressive NHL (n = 17) who had PET-CT performed as part of their initial staging and at follow-up were analyzed. Regardless of the extent of response to treatment, there was no single case in which the disease progressed outside of the initially involved FOV (0/44, 95% CI 0-0.08). This was true even in cases of disease progression, including in the setting of relapse. Our findings suggest that limited PET-CT analysis of the initially involved FOV in patients with early-stage curable lymphoma may be satisfactory for response assessment.

Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-1854.
Klose T, Leidl R, Buchmann I, Brambs HJ, Reske SN: Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 2000;27:1457-1464.
Kwee TC, Kwee RM, Nievelstein RA: Imaging in staging of malignant lymphoma: a systematic review. Blood 2008;111:504-516.
Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, Bruzzi JF: Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol 2010;194:W91-W103.
Huang B, Law MW, Khong PL: Whole-body PETCT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251:166-174.
Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, EORTC-GELA H8 Trial: Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-1927.
Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013-1022.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in Lymphoma: Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-578.
Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ: The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. Ann Hematol 2009;88:425-432.
Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F: Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol 2011;22:671-680.
Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, Beyer T: Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005;46:608-613.
Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Lacasce AS: High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 2012;53:1113-1116.
Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M: Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248:254-263.
von Schulthess GK, Steinert HC, Hany TF: Integrated PET/CT: Current applications and future directions. Radiology 2006;238:405-422.
Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J: Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med Technol 2010;38:6-17.
Berger M, Gould MK, Barnett PG: The cost of positron emission tomography in six United States veterans affairs hospitals and two academic medical centers. AJR Am J Roentgenol 2003;181:359-365.
Dinan MA, Curtis LH, Hammill BG, Patz EF Jr, Abernethy AP, Shea AM, Schulman KA: Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 2010;303:1625-1631.
Sammer MB, Shulkin BL, Alessio A, Parisi MT: Role of limited whole-body PET/CT in pediatric lymphoma. AJR Am J Roentgenol 2011;196:1047-1055.
Sanghera B, Sonoda LI, Hart J, Vivian G, Mills T, Wong WL: Age and dose-limited PET-CT scan regime in lymphoma: between the devil and the deep blue sea? Radiat Prot Dosimetry 2011;150:381-384.
Sonoda LI, Sanghera B, Wong WL: Investigation of dose minimisation protocol for (18)F-FDG PET-CT in the management of lymphoma postchemotherapy followup. Scientific World Journal 2012;2012:208135.
Connors JM: Clinical manifestations and natural history of Hodgkin's lymphoma. Cancer J 2009;15:124-128.
Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD: Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2001;50:971-977.
Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD: Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys 1997;39:609-616.
Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A: Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 2006;78:1-5.
Sanz L, Lopez-Guillermo A, Martinez C, Bosch F, Esteve J, Cobo F, Montoto S, Perales M, Blade J, Cervantes F, Nomdedeu B, Campo E, Montserrat E: Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. Eur J Haematol 1998;61:59-64.
Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH: Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 2012;118:4156-4165.
Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M: Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol 2002;69:41-44.
Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, Ferme C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F, Groupe d'Etude des Lymphomes de l'Adulte: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787-792.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.